Search All News
Cancer patients are especially vulnerable to COVID and would benefit from the protection the vaccine offers, says Gary Schwartz, MD, deputy director of the Herbert Irving Comprehensive Cancer Center.
A new analysis of almost 10,000 patients found that tumors could be stratified into 112 subtypes regardless of the cancer’s origin.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
Source:The New York TimesJune 23, 2016
- June 22, 2016
New research suggests that direct transmission of cancer among marine animals may be much more common than once thought.
- June 22, 2016
Cancer centers announce the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.
- June 16, 2016
One out of four breast cancer patients skipped hormonal therapy if they previously avoided treating chronic conditions, Columbia researchers found.
- March 31, 2016
An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA levels who had more aggressive disease.
- February 8, 2016
A Super Bowl ad has launched a new campaign at NewYork-Presbyterian Hospital that showcases Columbia and Weill Cornell expertise in cancer, particularly immunotherapy.
- January 28, 2016
A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
- January 27, 2016
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation’s top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer.
- January 20, 2016
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
- January 19, 2016
A new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears to have fewer side effects than a previous therapy.